Integral Molecular, Optimeos partner on long-lasting antibody therapeutics

By The Science Advisory Board staff writers

January 8, 2021 -- Integral Molecular and Optimeos Life Sciences have partnered to develop novel antibody therapeutics using long-acting, sustained delivery formulations.

In the partnership, Integral will use its MPS antibody discovery platform while Optimeos will use its inverse flash nanoprecipitation (iFNP) technology to reduce the frequency of injections for patients.

The MPS platform is capable of isolating antibodies against difficult proteins, overcoming traditional challenges such as target concentration and structurally complex antigens.

The iFNP technology was originally developed by Robert Prud'homme, PhD, at Princeton University, and it allows for the robust and scalable incorporation of therapeutic antibodies and other biologics into customizable nanoparticles. Prud'homme is also the co-founder and chief scientific officer of Optimeos.

Financial details of the partnership were not disclosed.

Integral Molecular touts Pa. grant to advance COVID-19 research
Integral Molecular was awarded over $520,000 from the state of Pennsylvania to leverage its technologies in COVID-19 research. The grant will enable the...
Integral Molecular adds to its antibody discovery platform
Integral Molecular has developed humanized chicken antibody technology and incorporated it into its MPS antibody discovery platform for multipass membrane...
Integral Molecular aids with safety testing of COVID-19 antibodies
Integral Molecular is applying its membrane proteome array technology for antibody specificity profiling to accelerate development of SARS-CoV-2 therapeutic...
Integral Molecular wins COVID-19 NIAID award
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded Integral Molecular $1 million to help discover vaccines and therapeutics...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter